Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ANTIPSYCHOTIC AGENTS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 145 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Ghaemi, SN
      On defining 'mood stabilizer'

      BIPOLAR DISORDERS
    2. Rothermundt, M; Missler, U; Arolt, V; Peters, M; Leadbeater, J; Wiesmann, M; Rudolf, S; Wandinger, KP; Kirchner, H
      Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology

      MOLECULAR PSYCHIATRY
    3. Ananth, J; Burgoyne, KS; Gadasalli, R; Aquino, S
      How do the atypical antipsychotics work?

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    4. Diaz, E; Levine, HB; Sullivan, MC; Sernyak, MJ; Hawkins, KA; Cramer, JA; Woods, SW
      Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    5. Tempier, R; Pawliuk, N
      Influence of novel and conventional antipsychotic medication on subjectivequality of life

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    6. Purdon, SE; Malla, A; Labelle, A; Lit, W
      Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    7. Khullar, A; Chue, P; Tibbo, P
      Quetiapine and obsessive-compulsive symptoms (OCS): case report and reviewof atypical antipsychotic-induced OCS

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    8. Huang, YS; Luedtke, RR; Freeman, RA; Wu, L; Mach, RH
      Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D-2 and D-3 receptors

      BIOORGANIC & MEDICINAL CHEMISTRY
    9. Melkersson, K; Khan, A; Hilding, A; Hulting, AL
      Different effects of antipsychotic drugs on insulin release in vitro

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    10. Melkersson, KI; Hulting, AL; Rane, AJ
      Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    11. Tie, H; Walker, BD; Singleton, CB; Bursill, JA; Wyse, KR; Campbell, TJ; Valenzuela, SM; Breit, SN
      Clozapine and sudden death

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    12. Miyamoto, Y; Yamada, K; Noda, Y; Mori, H; Mishina, M; Nabeshima, T
      Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon 1 subunit

      JOURNAL OF NEUROSCIENCE
    13. Sarkar, J; Jones, N; Sullivan, G
      A case of depersonalization-derealization syndrome during treatment with quetiapine

      JOURNAL OF PSYCHOPHARMACOLOGY
    14. Licht, RW; Bysted, M; Christensen, H
      Fixed-dosed risperidone in mania: an open experimental trial

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    15. Zhang, ZJ; Reynolds, GP; Ramchand, CN; Peet, M; Shah, S
      Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia

      ACTA PHARMACOLOGICA SINICA
    16. Czekalla, J; Beasley, CM; Dellva, MA; Berg, PH; Grundy, S
      Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis

      JOURNAL OF CLINICAL PSYCHIATRY
    17. Zefirova, ON; Zefirov, NS
      Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors

      USPEKHI KHIMII
    18. Rojas, P; Arancibia, P; Bravo, V; Varela, S
      Diabetes mellitus associated with olanzapine use

      REVISTA MEDICA DE CHILE
    19. Schillevoort, I; de Boer, A; Herings, RMC; Roos, RAC; Jansen, PAF; Leufkens, HGM
      Antipsychotic-induced extrapyramidal syndromes - Risperidone compared withlow- and high-potency conventional antipsychotic drugs

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    20. Dekeyne, A; Rivet, JM; Gobert, A; Millan, MJ
      Generalization of serotonin (5-HT)(1A) agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminativestimuli elicited by PD128,907 and 7-OH-DPAT

      NEUROPHARMACOLOGY
    21. Audinot, V; Newman-Tancredi, A; Millan, MJ
      Constitutive activity at serotonin 5-HT1D receptors: detection by homologous GTP gamma S versus [S-35]-GTP gamma S binding isotherms

      NEUROPHARMACOLOGY
    22. Bymaster, FP; Falcone, JF; Bauzon, D; Kennedy, JS; Schenck, K; DeLapp, NW; Cohen, ML
      Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

      EUROPEAN JOURNAL OF PHARMACOLOGY
    23. Narita, M; Yoshizawa, K; Nomura, M; Aoki, K; Suzuki, T
      Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine

      EUROPEAN JOURNAL OF PHARMACOLOGY
    24. Kampman, O; Lehtinen, K; Lassila, V
      The reliability of compliance assessments performed by doctors and patients during neuroleptic treatment: a comparison of compliance ratings

      ACTA PSYCHIATRICA SCANDINAVICA
    25. Ruhe, HG; Becker, HE; Jessurun, P; Marees, CH; Heeringa, M; Vermeulen, HDB
      Agranulocytosis and granulocytopenia associated with quetiapine

      ACTA PSYCHIATRICA SCANDINAVICA
    26. Bosveld-van Haandel, LJM; Slooff, CJ; van den Bosch, RJ
      Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments

      ACTA PSYCHIATRICA SCANDINAVICA
    27. Wahlbeck, K; Tuunainen, A; Ahokas, A; Leucht, S
      Dropout rates in randomised antipsychotic drug trials

      PSYCHOPHARMACOLOGY
    28. Tohen, M; Jacobs, TG; Feldman, PD
      Onset of action of antipsychotics in the treatment of mania

      BIPOLAR DISORDERS
    29. Levine, J; Chengappa, KNR; Brar, JS; Gershon, S; Yablonsky, E; Stapf, D; Kupfer, DJ
      Psychotropic drug prescription patterns among patients with bipolar I disorder

      BIPOLAR DISORDERS
    30. Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A
      Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    31. Nakazato, A; Okuyama, S
      Recent advances in novel atypical antipsychotic agents: potential therapeutic agents for the treatment of schizophrenia

      EXPERT OPINION ON THERAPEUTIC PATENTS
    32. Hawkins, KA
      Novel antipsychotics and the neuropsychological deficiencies of schizophrenia

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    33. Purdon, SE
      Measuring neuropsychological change in schizophrenia with novel antipsychotic medications

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    34. Galletly, CA; Clark, CR; MacFarlane, AC
      Treating cognitive dysfunction in patients with schizophrenia

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    35. Stip, E
      Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    36. Welch, R; Chue, P
      Antipsychotic agents and QT changes

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    37. Kapur, S; Seeman, P
      Antipsychotic agents differ in how fast they come off the dopamine D-2 receptors. Implications for atypical antipsychotic action

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    38. Falsetti, AE
      Risperidone for control of agitation in dementia patients

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    39. Worrel, JA; Marken, PA; Beckman, SE; Ruehter, VL
      Atypical antipsychotic agents: A critical review

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    40. Perrone, R; Berardi, F; Colabufo, NA; Leopoldo, M; Tortorella, V
      1-substituted-4-[3-(1,2,3,4-tetrahydro-5-or 7-methoxynaphthalen-1-yl)propyl]piperazines: Influence of the N-1 piperazine substituent on 5-HT1A receptor affinity and selectivity versus D-2 and alpha(1) receptors. Part 6

      BIOORGANIC & MEDICINAL CHEMISTRY
    41. Comoy, C; Guerin, V; Pfeiffer, B; Rettori, MC; Renard, P; Guillaumet, G
      Substituted 3-amino and/or 3-aminomethyl-3,4-dihydro-2H-1-benzopyrans: Synthesis and biological activity

      BIOORGANIC & MEDICINAL CHEMISTRY
    42. Einsiedel, J; Thomas, C; Hubner, H; Gmeiner, P
      Phenyloxazoles and phenylthiazoles as benzamide bioisosteres: Synthesis and dopamine receptor binding profiles

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    43. Mazzocato, C; Stiefel, F; Buclin, T; Berney, A
      Psychopharmacology in supportive care of cancer: a review for the clinician - II. Neuroleptics

      SUPPORTIVE CARE IN CANCER
    44. Tannirandorn, P; Epstein, S
      Drug-induced bone loss

      OSTEOPOROSIS INTERNATIONAL
    45. Sallee, FR; Kurlan, R; Goetz, CG; Singer, H; Scahill, L; Law, G; Dittman, VM; Chappell, PB
      Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study

      JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
    46. Ljubin, T; Milas, DZ; Mimica, N; Folnegovic-Smalc, V; Makaric, G
      A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    47. Hrib, NJ
      The dopamine D-4 receptor: a controversial therapeutic target

      DRUGS OF THE FUTURE
    48. Wahlbeck, K; Cheine, M; Tuisku, K; Ahokas, A; Joffe, G; Rimon, R
      Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    49. Fu, Y; Zhu, ZT; Chen, LJ; Yu, LP; Jin, GZ
      Behavioral characteristics of olanzapine: an atypical neuroleptic

      ACTA PHARMACOLOGICA SINICA
    50. Guan, HJ; Dai, J; Zhu, XZ
      Atypical antipsychotic effects of quetiapine fumarate in animal models

      ACTA PHARMACOLOGICA SINICA
    51. Moser, PC; Hitchcock, JM; Lister, S; Moran, PM
      The pharmacology of latent inhibition as an animal model of schizophrenia

      BRAIN RESEARCH REVIEWS
    52. Guille, C; Sachs, GS; Ghaemi, SN
      A naturalistic comparison of clozapine, risperidone, and olanzapine in thetreatment of bipolar disorder

      JOURNAL OF CLINICAL PSYCHIATRY
    53. David, SR; Taylor, CC; Kinon, BJ; Breier, A
      The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

      CLINICAL THERAPEUTICS
    54. Hyman, SE
      The genetics of mental illness: implications for practice

      BULLETIN OF THE WORLD HEALTH ORGANIZATION
    55. Gazi, L; Schoeffter, P; Nunn, C; Croskery, K; Hoyer, D; Feuerbach, D
      Cloning, expression, functional coupling and pharmacological characterization of the rat dopamine D-4 receptor

      NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    56. Millan, MJ
      Improving the treatment of schizophrenia: Focus on serotonin (5-HT)(1A) receptors

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    57. Millan, MJ; Gobert, A; Newman-Tancredi, A; Lejeune, F; Cussac, D; Rivet, JM; Audinot, V; Dubuffet, T; Lavielle, G
      S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    58. Millan, MJ; Dekeyne, A; Rivet, JM; Dubuffet, T; Lavielle, G; Brocco, M
      S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    59. Schuld, A; Kraus, T; Hinze-Selch, D; Haack, M; Pollmacher, T
      Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia

      ACTA PSYCHIATRICA SCANDINAVICA
    60. Kelly, BD; Kennedy, N; Shanley, D
      Delusion and desire: erotomania revisited

      ACTA PSYCHIATRICA SCANDINAVICA
    61. Cooper, SJ; Butler, A; Tweed, J; Welch, C; Raniwalla, J
      Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia

      PSYCHOPHARMACOLOGY
    62. Remington, G; Chong, SA
      Conventional versus novel antipsychotics: changing concepts and clinical implications

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    63. Wolff, AL; O'Driscoll, GA
      Motor deficits and schizophrenia: the evidence from neuroleptic-naive patients and populations at risk

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    64. Dursun, SM; Patel, JKM; Burke, JG; Reveley, MA
      Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    65. Oyewumi, LK; McKnight, M; Cernovsky, ZZ
      Lithium dosage and leukocyte counts in psychiatric patients

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    66. Hammond, CM; Pierson, JF; Grande, TP; Munetz, MR; Wilson, DR; Pathak, DS
      Economic evaluation of risperidone in an outpatient population

      ANNALS OF PHARMACOTHERAPY
    67. Hammond, PS; Cheney, JT; Johnston, DE; Ehrenkaufer, RL; Luedtke, RR; Mach, RH
      Synthesis, in vitro dopamine D-2 and D-3 receptor binding and quantitativestructure-activity studies on substituted 2,3-dimethoxy-N-(1-benzyl-4-piperidinyl)benzamides and related compounds.

      MEDICINAL CHEMISTRY RESEARCH
    68. Burnett, DM; Kennedy, RE; Cifu, DX; Levenson, J
      Using atypical neuroleptic drugs to treat agitation in patients with a brain injury: a review

      NEUROREHABILITATION
    69. Langer, O; Halldin, C; Dolle, F; Swahn, CG; Olsson, H; Karlsson, P; Hall, H; Sandell, J; Lundkvist, C; Vaufrey, F; Loc'h, C; Crouzel, C; Maziere, B; Farde, L
      Carbon-11 epidepride: A suitable radioligand for PET investigation of striatal and extrastriatal dopamine D-2 receptors

      NUCLEAR MEDICINE AND BIOLOGY
    70. Homan, EJ; Wikstrom, HV; Grol, CJ
      Molecular modeling of the dopamine D-2 and serotonin 5-HT1A receptor binding modes of the enantiomers of 5-OMe-BPAT

      BIOORGANIC & MEDICINAL CHEMISTRY
    71. Homan, EJ; Tulp, MTM; Nilsson, JE; Wikstrom, HV; Grol, CJ
      C5-substituted derivatives of 5-OMe-BPAT: Synthesis and interactions with dopamine D-2 and serotonin 5-HT1A receptors

      BIOORGANIC & MEDICINAL CHEMISTRY
    72. Brylewski, J; Duggan, L
      Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials

      JOURNAL OF INTELLECTUAL DISABILITY RESEARCH
    73. Dubuffet, T; Newman-Tancredi, A; Cussac, D; Audinot, V; Loutz, A; Millan, MJ; Lavielle, G
      Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D-3 receptor antagonists

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    74. Nakahara, K; Tanaka, H; Masutani, K; Yanagida, T; Kashiwagi, M; Mizumasa, T; Masuda, K; Hirakata, H; Fujishima, M
      The value of computed tomography and magnetic resonance imaging to diagnose rhabdomyolysis in acute renal failure

      NEPHROLOGY DIALYSIS TRANSPLANTATION
    75. Lavalaye, J; Linszen, DH; Booij, J; Reneman, L; Gersons, BPR; van Royen, EA
      Dopamine D-2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia

      PSYCHIATRY RESEARCH-NEUROIMAGING
    76. Petty, RG
      Prolactin and antipsychotic medications: mechanism of action

      SCHIZOPHRENIA RESEARCH
    77. Lera, G; Zirulnik, J
      Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism

      MOVEMENT DISORDERS
    78. Spivak, B; Lamschtein, C; Talmon, Y; Guy, N; Mester, R; Feinberg, I; Kotler, M; Weizman, A
      The impact of clozapine treatment on serum lipids in chronic schizophrenicpatients

      CLINICAL NEUROPHARMACOLOGY
    79. Spivak, B; Musin, E; Mester, R; Gonen, N; Talmon, Y; Guy, N; Roitman, S; Kupchik, M; Kotler, M; Weizman, A
      The effect of long-term antipsychotic treatment on the body weight of patients suffering from chronic schizophrenia: clozapine versus classical antipsychotic agents

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    80. Meltzer, HY
      Outcome in schizophrenia: Beyond symptom reduction

      JOURNAL OF CLINICAL PSYCHIATRY
    81. Shinkai, T; Ohmori, O; Kojima, H; Terao, T; Suzuki, T; Abe, K
      Association study of the 5-HT6 receptor gene in schizophrenia

      AMERICAN JOURNAL OF MEDICAL GENETICS
    82. Mohn, AR; Gainetdinov, RR; Caron, MG; Koller, BH
      Mice with reduced NMDA receptor expression display behaviors related to schizophrenia

      CELL
    83. Newman-Tancredi, A; Cussac, D; Audinot, V; Millan, MJ
      Actions of roxindole at recombinant human dopamine D-2, D-3 and D-4 and serotonim 5-HT1A, 5-HT1B and 5-HT1D receptors

      NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    84. Herrick-Davis, K; Grinde, E; Niswander, CM
      Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: Implications for serotonergic signal transduction

      JOURNAL OF NEUROCHEMISTRY
    85. Pinna, GRA; Curzu, MM; Sechi, M; Chelucci, G; Maciocco, E
      Synthesis and dopamine D-2-Iike receptor binding affinity of substituted 5-phenyl-pyrrole-3-carboxamides

      FARMACO
    86. Malinka, W; Sieklucka-Dziuba, M; Rajtar, G; Rubaj, A; Kleinrok, Z
      Synthesis and pharmacological screening of some N-(4-substituted-piperazin-1-ylalkyl)-3,4-pyrroledicarboximides

      FARMACO
    87. Gazi, L; Bobirnac, I; Danzeisen, M; Schupbach, E; Langenegger, D; Sommer, B; Hoyer, D; Tricklebank, M; Schoeffter, P
      Receptor density as a factor governing the efficacy of the dopamine D-4 receptor ligands, L-745,870 and U-101958 at human recombinant D-4.4 receptorsexpressed in CHO cells

      BRITISH JOURNAL OF PHARMACOLOGY
    88. Morera, AL; Barreiro, P; Cano-Munoz, JL
      Risperidone and clozapine combination for the treatment of refractory schizophrenia

      ACTA PSYCHIATRICA SCANDINAVICA
    89. Kostakoglu, AE; Rezaki, M; Gogus, A
      Early relapse of psychotic symptoms after an initial response to olanzapine

      ACTA PSYCHIATRICA SCANDINAVICA
    90. ISKEDJIAN M; HUX M; REMINGTON GJ
      THE CANADIAN EXPERIENCE WITH RISPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA - AN OVERVIEW

      Journal of psychiatry & neuroscience
    91. TAKAHASHI Y; KUSUMI I; ISHIKANE T; MATSUBARA S; KOYAMA T
      IN-VIVO OCCUPATION OF DOPAMINE D-1, D-2 AND SEROTONIN (5-HT)(2A) RECEPTORS BY SERTINDOLE IN THE RAT-BRAIN

      Journal of psychiatry & neuroscience
    92. BEVER KA; PERRY PJ
      OLANZAPINE - A SEROTONIN-DOPAMINE-RECEPTOR ANTAGONIST FOR ANTIPSYCHOTIC THERAPY

      American journal of health-system pharmacy
    93. HAMILTON SH; REVICKI DA; GENDUSO LA; BEASLEY CM
      OLANZAPINE VERSUS PLACEBO AND HALOPERIDOL - QUALITY-OF-LIFE AND EFFICACY RESULTS OF THE NORTH-AMERICAN DOUBLE-BLIND TRIAL

      Neuropsychopharmacology
    94. FURNISS L; CRAIG SKL; BURNS A
      MEDICATION USE IN NURSING-HOMES FOR ELDERLY PEOPLE

      International journal of geriatric psychiatry
    95. BRODERICK PA; PIERCEY MF
      CLOZAPINE, HALOPERIDOL, AND THE D-4 ANTAGONIST PNU-101387G - IN-VIVO EFFECTS ON MESOCORTICAL, MESOLIMBIC, AND NIGROSTRIATAL DOPAMINE AND SEROTONIN RELEASE

      Journal of neural transmission
    96. NILSSON LB
      HIGH-SENSITIVITY DETERMINATION OF THE REMOXIPRIDE HYDROQUINONE METABOLITE NCQ-344 IN PLASMA BY COUPLED-COLUMN REVERSED-PHASE LIQUID-CHROMATOGRAPHY AND ELECTROCHEMICAL DETECTION

      BMC. Biomedical chromatography
    97. MOLLER HJ; GAGIANO CA; ADDINGTON DE; VONKNORRING L; TORRESPLANK JF; GAUSSARES C
      LONG-TERM TREATMENT OF CHRONIC-SCHIZOPHRENIA WITH RISPERIDONE - AN OPEN-LABEL, MULTICENTER STUDY OF 386 PATIENTS

      International clinical psychopharmacology
    98. Ganguli, R; Brar, JS
      The effects of risperidone and olanzapine on the indications for clozapine

      PSYCHOPHARMACOLOGY BULLETIN
    99. MURPHY GM; LIM KO; WIENEKE M; ELLIS WG; FORNO LS; HOFF AL; NORDAHL T
      NO NEUROPATHOLOGIC EVIDENCE FOR AN INCREASED FREQUENCY OF ALZHEIMERS-DISEASE AMONG ELDERLY SCHIZOPHRENICS

      Biological psychiatry
    100. LICHT RW
      DRUG-TREATMENT OF MANIA - A CRITICAL-REVIEW

      Acta psychiatrica Scandinavica


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 12:09:45